Strs Ohio Buys New Shares in Hims & Hers Health, Inc. $HIMS

Strs Ohio bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 49,700 shares of the company’s stock, valued at approximately $1,469,000.

Several other institutional investors and hedge funds also recently made changes to their positions in HIMS. Nuveen LLC bought a new position in shares of Hims & Hers Health during the 1st quarter valued at $58,403,000. Yong Rong HK Asset Management Ltd grew its holdings in Hims & Hers Health by 41.2% in the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock worth $70,920,000 after acquiring an additional 700,100 shares during the last quarter. CloudAlpha Capital Management Limited Hong Kong bought a new stake in Hims & Hers Health in the 1st quarter worth $20,580,000. Jump Financial LLC grew its holdings in Hims & Hers Health by 633.2% in the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock worth $21,437,000 after acquiring an additional 626,496 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in Hims & Hers Health by 37.9% in the 4th quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company’s stock worth $47,571,000 after acquiring an additional 540,274 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

HIMS has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Morgan Stanley reissued an “equal weight” rating and issued a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Finally, Truist Financial cut their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Trading Down 5.8%

Shares of NYSE HIMS opened at $50.83 on Wednesday. Hims & Hers Health, Inc. has a 1 year low of $15.73 and a 1 year high of $72.98. The stock has a market cap of $11.49 billion, a P/E ratio of 63.54, a price-to-earnings-growth ratio of 3.64 and a beta of 2.14. The firm has a 50-day moving average of $50.41 and a 200 day moving average of $45.40. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. During the same period last year, the business earned $0.06 earnings per share. The company’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares of the company’s stock, valued at $112,023,016.02. This trade represents a 22.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the transaction, the chief financial officer directly owned 63,222 shares of the company’s stock, valued at approximately $2,987,239.50. This trade represents a 26.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,110,347 shares of company stock valued at $55,342,532. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.